- Projects & figures
- News & Events
- Managing your project
- About ERC
A targeted and personalised method for triggering the body’s immune response could transform how we treat cancer. Thanks to a grant from the European Research Council (ERC), an inspired idea has been developed in the lab and turned into a ground-breaking commercial opportunity.
Stressed plants typically stop growing. With her ERC grant, Prof. Ana Caño-Delgado has developed and is applying an innovative approach to generate drought-resistant plants that continue growing. This could play an important role in ensuring food security when water is scarce.
New families of proteins and enzymes will enable the development of novel plant-based biomaterials, potentially providing viable sustainable and renewable alternatives to plastics and other fossil-fuel-derived materials and chemicals.
Maternal microbiota is crucial for the future health of a child. The transmission of microbes to offspring is a process that begins in the uterus and is influenced by the delivery method, breastfeeding and the mother’s diet. However, the mechanisms behind the protective role of maternal microbes on the baby’s health are not yet fully understood.
EU-funded researchers planted, harvested, processed and analysed the life cycle of woody crops to establish how efficient and environmentally friendly they are as a source of fuel for electricity and heat.
Tamoxifen, a drug used in breast cancer treatment, may be repositioned to treat pancreatic cancer
Pancreatic cancer is the 4th leading cause of death by cancer in Europe. It has a very low survival rate with less than 1 per cent of sufferers surviving for 10 or more years. Over the last 40 years the survival rate has not significantly changed and finding an effective therapy has become a pressing challenge in cancer research. A team based at Imperial College London led by Armando Del Río Hernández, has now demonstrated that a well-known drug could be effective to fight this deadly and other forms of cancer, such as liver cancer.
CRISPR is a widely used molecular biology tool exploiting an immune process discovered in bacteria. Dr David Bikard studies CRISPR in bacterial cells, in conjunction with different DNA repair systems, to create even newer tools. He hopes to gain insight into bacterial genetics, and develop increasingly effective medical treatments.
Colorectal cancer (CRC) is the second most common cause of cancer-related deaths. European researchers developed novel ex vivo three-dimensional organoid cultures that replicate genetic events in CRC, as tools to test novel therapeutics.
In only three years’ time, Dr Jan Tkač went from being the first ERC grantee in Slovakia to obtaining the “2015 Scientist of the Year” award. His research in the field of glyconomics could emerge as a turning point for the diagnosis of cell-related diseases.
Maria Brandão de Vasconcelos, together with her colleague Filipa Matos Baptista, Henrique Veiga-Fernandes (ERC grantee), Diogo Fonseca Pereira and Sílvia Arroz Madeira, founded StemCell2MAX in 2015. The company is a biotechnology start-up, specialised in cell based therapies, including novel solutions to multiply the scarcely available blood stem cells, addressing an enormous demand for research and cancer treatment. StemCell2MAX technology is based on Prof. Veiga-Fernandes's ground-breaking discoveries in hematopoietic stem cell biology.
Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."